Overview

The CDER Ombudsperson receives and investigates questions and complaints that arise between the FDA’s Center for Drug Evaluation and Research and external stakeholders. This enhances regulatory transparency and reduces the uncertainty companies face during the new drug approval process.

Informal Dispute Resolution

By resolving disputes informally, the Ombudsperson enables companies to address issues quickly without lengthy litigation. This directly impacts drug development timelines, helping new therapies reach patients more rapidly.

Early Mediation Benefits

Historically, conflicts between the FDA and companies often escalated to legal proceedings, but the Ombudsperson’s mediation role identifies and addresses disputes early. This reduces costs and enhances regulatory credibility. Regulatory agencies in other countries are also exploring similar Ombudsperson models.

Expansion Implications

If the use of the Ombudsperson expands, biotech companies can anticipate smoother communication with regulators early in development. This sends a positive signal to investors and may accelerate the pace of industry innovation. However, if the Ombudsperson’s authority and procedures are not clearly defined, there is a risk of confusion.